Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Seattle, Washington

Cancer surgery and procedure trials in Seattle, WA

89 cancer surgery and procedure studies are recruiting participants at sites in Seattle as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Seattle at a glance

  • 89 studies are recruiting at a site in Seattle.
  • By phase: Phase 1 (4), Phase 1/2 (6), Phase 2 (42), Phase 3 (24), No phase (6), Observational (7). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (74), government (15).
  • By research area: Lymphoma (38), Lung Cancer (16), Prostate Cancer (15), Breast Cancer (13), Pancreatic Cancer (6), Melanoma (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Seattle

Basic details from each study's public record (the 30 most recently updated of 89). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT05564377 · updated
  2. [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Washington
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT06502691 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06058377 · updated
  4. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Swedish Medical Center-Ballard Campus · Swedish Medical Center-Cherry Hill · Swedish Medical Center-First Hill
    Registry record
    NCT05334069 · updated
  5. A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Washington
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT07112053 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Lung cancer studies recruiting in Seattle

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06498635 · updated
  2. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT07388524 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06096844 · updated
  4. Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Fred Hutchinson Cancer Center · University of Washington Medical Center - Montlake
    Registry record
    NCT03191149 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Seattle

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    FHCC at Northwest Hospital · Fred Hutchinson Cancer Center · Swedish Medical Center-Ballard Campus
    Registry record
    NCT04423211 · updated
  2. Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06632977 · updated
  3. Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT07200830 · updated
  4. Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT07466498 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Melanoma studies recruiting in Seattle

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Fred Hutchinson Cancer Center · University of Washington Medical Center - Montlake
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Seattle, WA on ClinicalTrials.gov.

Lymphoma studies recruiting in Seattle

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Seattle Children's Hospital
    Registry record
    NCT06317662 · updated
  2. Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Washington
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT06784726 · updated
  3. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Seattle Children's Hospital
    Registry record
    NCT04726241 · updated
  4. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study sites
    Swedish Medical Center-Ballard Campus · Swedish Medical Center-Cherry Hill · Swedish Medical Center-First Hill
    Registry record
    NCT06724237 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    FHCC at Northwest Hospital · Fred Hutchinson Cancer Center · Swedish Medical Center-First Hill
    Registry record
    NCT04269902 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Seattle Children's Hospital
    Registry record
    NCT04546399 · updated
  7. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT04840602 · updated
  8. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Seattle Children's Hospital
    Registry record
    NCT05675410 · updated
  9. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06649812 · updated
  10. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT03150693 · updated
  11. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT05976763 · updated
  12. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT07215910 · updated
  13. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT07321652 · updated
  14. Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT06839053 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Seattle, WA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Seattle

  1. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT04858334 · updated
  2. Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Washington
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT07645651 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Ask about studies near Seattle

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call